{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:00:38Z","timestamp":1788778838919,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,8,9]],"date-time":"2017-08-09T00:00:00Z","timestamp":1502236800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s12185-017-2294-1","type":"journal-article","created":{"date-parts":[[2017,8,9]],"date-time":"2017-08-09T06:53:25Z","timestamp":1502261605000},"page":"666-674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib"],"prefix":"10.1007","volume":"106","author":[{"given":"Ryujiro","family":"Hara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-0823","authenticated-orcid":false,"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Matsusita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Kikkawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ohgiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohmachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Shirasugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,9]]},"reference":[{"key":"2294_CR1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/B978-0-12-800173-8.00004-0","volume":"39","author":"HM Korashy","year":"2014","unstructured":"Korashy HM, Rahman AF, Kassem MG. Dasatinib. Profiles Drug Subst Excip Relat Methodol. 2014;39:205\u201337.","journal-title":"Profiles Drug Subst Excip Relat Methodol."},{"key":"2294_CR2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-642-54490-3_2","volume":"201","author":"M Lindauer","year":"2014","unstructured":"Lindauer M, Hochhaus A. Dasatinib. Recent Results Cancer Res. 2014;201:27\u201365.","journal-title":"Recent Results Cancer Res"},{"issue":"24","key":"2294_CR3","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260\u201370.","journal-title":"N Engl J Med"},{"issue":"5","key":"2294_CR4","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123\u20139.","journal-title":"Blood"},{"issue":"19","key":"2294_CR5","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","volume":"120","author":"JP Radich","year":"2012","unstructured":"Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, et al. A randomized trial of dasatinib 100\u00a0mg versus imatinib 400\u00a0mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012;120(19):3898\u2013905.","journal-title":"Blood"},{"issue":"2","key":"2294_CR6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.critrevonc.2013.10.005","volume":"89","author":"S Paydas","year":"2014","unstructured":"Paydas S. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect? Crit Rev Oncol Hematol. 2014;89(2):242\u20137.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2294_CR7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4161\/cbt.27310","volume":"15","author":"ZY Qiu","year":"2014","unstructured":"Qiu ZY, Xu W, Li JY. Large granular lymphocytosis during dasatinib therapy. Cancer Biol Ther. 2014;15(3):247\u201355.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"2294_CR8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2\u00a0years. Blood. 2007;109(1):58\u201360.","journal-title":"Blood"},{"issue":"11","key":"2294_CR9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029\u201335.","journal-title":"Lancet Oncol."},{"issue":"4","key":"2294_CR10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515\u201322.","journal-title":"Blood"},{"issue":"9","key":"2294_CR11","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/cas.12216","volume":"104","author":"I Mizoguchi","year":"2013","unstructured":"Mizoguchi I, Yoshimoto T, Katagiri S, Mizuguchi J, Tauchi T, Kimura Y, et al. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci. 2013;104(9):1146\u201353.","journal-title":"Cancer Sci"},{"issue":"12","key":"2294_CR12","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1\u00a0year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2(12):e528\u201335.","journal-title":"Lancet Haematol."},{"issue":"1","key":"2294_CR13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1158\/0008-5472.CAN-05-2776","volume":"66","author":"T Hayashi","year":"2006","unstructured":"Hayashi T, Imai K, Morishita Y, Hayashi I, Kusunoki Y, Nakachi K. Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance. Cancer Res. 2006;66(1):563\u201370.","journal-title":"Cancer Res"},{"issue":"2","key":"2294_CR14","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/carcin\/bgm260","volume":"29","author":"H Furue","year":"2008","unstructured":"Furue H, Matsuo K, Kumimoto H, Hiraki A, Suzuki T, Yatabe Y, et al. Decreased risk of colorectal cancer with the high natural killer cell activity NKG2D genotype in Japanese. Carcinogenesis. 2008;29(2):316\u201320.","journal-title":"Carcinogenesis"},{"issue":"10","key":"2294_CR15","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3324\/haematol.2009.008318","volume":"94","author":"JL Espinoza","year":"2009","unstructured":"Espinoza JL, Takami A, Onizuka M, Sao H, Akiyama H, Miyamura K, et al. NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies. Haematologica. 2009;94(10):1427\u201334.","journal-title":"Haematologica"},{"issue":"175","key":"2294_CR16","doi-asserted-by":"crossref","first-page":"ra36","DOI":"10.1126\/scisignal.2001325","volume":"4","author":"S Mesecke","year":"2011","unstructured":"Mesecke S, Urlaub D, Busch H, Eils R, Watzl C. Integration of activating and inhibitory receptor signaling by regulated phosphorylation of Vav1 in immune cells. Sci Signal. 2011;4(175):ra36.","journal-title":"Sci Signal."},{"issue":"6","key":"2294_CR17","doi-asserted-by":"crossref","first-page":"E916","DOI":"10.1002\/ijc.27537","volume":"131","author":"N Hassold","year":"2012","unstructured":"Hassold N, Seystahl K, Kempf K, Urlaub D, Zekl M, Einsele H, et al. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib. Int J Cancer. 2012;131(6):E916\u201327.","journal-title":"Int J Cancer"},{"issue":"8","key":"2294_CR18","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23(8):1398\u2013405.","journal-title":"Leukemia"},{"issue":"9","key":"2294_CR19","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24096","volume":"90","author":"N Iriyama","year":"2015","unstructured":"Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, et al. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study. Am J Hematol. 2015;90(9):819\u201324.","journal-title":"Am J Hematol"},{"issue":"10","key":"2294_CR20","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172\u20135.","journal-title":"Leukemia"},{"issue":"6","key":"2294_CR21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12185-015-1766-4","volume":"101","author":"J Amaki","year":"2015","unstructured":"Amaki J, Onizuka M, Ohmachi K, Aoyama Y, Hara R, Ichiki A, et al. Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy. Int J Hematol. 2015;101(6):543\u201353.","journal-title":"Int J Hematol"},{"issue":"1","key":"2294_CR22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ijc.23456","volume":"123","author":"H Furue","year":"2008","unstructured":"Furue H, Kumimoto H, Matsuo K, Suzuki T, Hasegawa Y, Shinoda M, et al. Opposite impact of NKG2D genotype by lifestyle exposure to risk of aerodigestive tract cancer among Japanese. Int J Cancer. 2008;123(1):181\u20136.","journal-title":"Int J Cancer"},{"issue":"1","key":"2294_CR23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jbspin.2015.06.010","volume":"83","author":"M Iwaszko","year":"2016","unstructured":"Iwaszko M, Swierkot J, Kolossa K, Jeka S, Wiland P, Bogunia-Kubik K. Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment. Jt Bone Spine. 2016;83(1):75\u20139.","journal-title":"Jt Bone Spine."},{"issue":"25","key":"2294_CR24","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1182\/blood-2012-03-416800","volume":"119","author":"J Tanaka","year":"2012","unstructured":"Tanaka J, Sugita J, Shiratori S, Shigematsu A, Imamura M. Dasatinib enhances the expansion of CD56+CD3\u2212 NK cells from cord blood. Blood. 2012;119(25):6175\u20136.","journal-title":"Blood"},{"issue":"3","key":"2294_CR25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/hon.2034","volume":"31","author":"T Uchiyama","year":"2013","unstructured":"Uchiyama T, Sato N, Narita M, Yamahira A, Iwabuchi M, Furukawa T, et al. Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study. Hematol Oncol. 2013;31(3):156\u201363.","journal-title":"Hematol Oncol"},{"issue":"6","key":"2294_CR26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1399-0039.2009.01235.x","volume":"73","author":"D Middleton","year":"2009","unstructured":"Middleton D, Diler AS, Meenagh A, Sleator C, Gourraud PA. Killer immunoglobulin-like receptors (KIR2DL2 and\/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia. Tissue Antigens. 2009;73(6):553\u201360.","journal-title":"Tissue Antigens"},{"issue":"11","key":"2294_CR27","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.exphem.2012.07.007","volume":"40","author":"A Kreutzman","year":"2012","unstructured":"Kreutzman A, Jaatinen T, Greco D, Vakkila E, Richter J, Ekblom M, et al. Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. Exp Hematol. 2012;40(11):906\u201313.","journal-title":"Exp Hematol."},{"issue":"12","key":"2294_CR28","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.exphem.2015.08.004","volume":"43","author":"G Caocci","year":"2015","unstructured":"Caocci G, Martino B, Greco M, Abruzzese E, Trawinska MM, Lai S, et al. Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. Exp Hematol. 2015;43(12):1015\u20138.","journal-title":"Exp Hematol."},{"issue":"2","key":"2294_CR29","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cell.2009.12.033","volume":"140","author":"B Yu","year":"2010","unstructured":"Yu B, Martins IR, Li P, Amarasinghe GK, Umetani J, Fernandez-Zapico ME, et al. Structural and energetic mechanisms of cooperative autoinhibition and activation of Vav1. Cell. 2010;140(2):246\u201356.","journal-title":"Cell"},{"issue":"3","key":"2294_CR30","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1084\/jem.188.3.549","volume":"188","author":"DD Billadeau","year":"1998","unstructured":"Billadeau DD, Brumbaugh KM, Dick CJ, Schoon RA, Bustelo XR, Leibson PJ. The Vav-Rac1 pathway in cytotoxic lymphocytes regulates the generation of cell-mediated killing. J Exp Med. 1998;188(3):549\u201359.","journal-title":"J Exp Med"},{"issue":"6","key":"2294_CR31","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.4049\/jimmunol.162.6.3148","volume":"162","author":"R Galandrini","year":"1999","unstructured":"Galandrini R, Palmieri G, Piccoli M, Frati L, Santoni A. Role for the Rac1 exchange factor Vav in the signaling pathways leading to NK cell cytotoxicity. J Immunol. 1999;162(6):3148\u201352.","journal-title":"J Immunol."},{"issue":"4","key":"2294_CR32","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/leu.2010.11","volume":"24","author":"KC Lee","year":"2010","unstructured":"Lee KC, Ouwehand I, Giannini AL, Thomas NS, Dibb NJ, Bijlmakers MJ. Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia. 2010;24(4):896\u2013900.","journal-title":"Leukemia"},{"issue":"3","key":"2294_CR33","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clim.2008.02.006","volume":"127","author":"S Blake","year":"2008","unstructured":"Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src\/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol. 2008;127(3):330\u20139.","journal-title":"Clin Immunol."},{"issue":"3","key":"2294_CR34","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1074\/jbc.275.3.2185","volume":"275","author":"MR Kuhne","year":"2000","unstructured":"Kuhne MR, Ku G, Weiss A. A guanine nucleotide exchange factor-independent function of Vav1 in transcriptional activation. J Biol Chem. 2000;275(3):2185\u201390.","journal-title":"J Biol Chem"},{"issue":"46","key":"2294_CR35","doi-asserted-by":"crossref","first-page":"15257","DOI":"10.1021\/bi051126h","volume":"44","author":"GK Amarasinghe","year":"2005","unstructured":"Amarasinghe GK, Rosen MK. Acidic region tyrosines provide access points for allosteric activation of the autoinhibited Vav1 Dbl homology domain. Biochemistry. 2005;44(46):15257\u201368.","journal-title":"Biochemistry"},{"issue":"50","key":"2294_CR36","doi-asserted-by":"crossref","first-page":"38257","DOI":"10.1074\/jbc.M608913200","volume":"281","author":"AV Miletic","year":"2006","unstructured":"Miletic AV, Sakata-Sogawa K, Hiroshima M, Hamann MJ, Gomez TS, Ota N, et al. Vav1 acidic region tyrosine 174 is required for the formation of T cell receptor-induced microclusters and is essential in T cell development and activation. J Biol Chem. 2006;281(50):38257\u201365.","journal-title":"J Biol Chem"},{"issue":"5","key":"2294_CR37","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1634\/theoncologist.2010-0408","volume":"16","author":"LN Puls","year":"2011","unstructured":"Puls LN, Eadens M, Messersmith W. Current status of SRC inhibitors in solid tumor malignancies. Oncologist. 2011;16(5):566\u201378.","journal-title":"Oncologist."},{"key":"2294_CR38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","volume":"94","author":"R Roskoski Jr","year":"2015","unstructured":"Roskoski R Jr. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol Res. 2015;94:9\u201325.","journal-title":"Pharmacol Res"},{"issue":"12","key":"2294_CR39","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ajh.23560","volume":"88","author":"L Falchi","year":"2013","unstructured":"Falchi L, Kantarjian HM, Wang X, Verma D, Quintas-Cardama A, O\u2019Brien S, et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013;88(12):1024\u20139.","journal-title":"Am J Hematol"},{"issue":"20","key":"2294_CR40","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333\u201340.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2294_CR41","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","volume":"129","author":"A Hughes","year":"2017","unstructured":"Hughes A, Clarson J, Tang C, Vidovic L, White DL, Hughes TP, et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood. 2017;129(9):1166\u201376.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-017-2294-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2294-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2294-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T22:31:33Z","timestamp":1692916293000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-017-2294-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,9]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["2294"],"URL":"https:\/\/doi.org\/10.1007\/s12185-017-2294-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,9]]}}}